Entecavir Dosing in Chronic Hepatitis B with Acute Kidney Injury
For adults with chronic hepatitis B and acute kidney injury, entecavir dosing must be adjusted based on creatinine clearance, with dose reductions required when CrCl falls below 50 mL/min. 1
Dose Adjustment Algorithm Based on Renal Function
The FDA-approved dosing adjustments for entecavir in renal impairment are as follows 1:
For Treatment-Naïve Patients (Standard 0.5 mg dose):
- CrCl ≥50 mL/min: 0.5 mg once daily
- CrCl 30 to <50 mL/min: 0.5 mg every 48 hours
- CrCl 10 to <30 mL/min: 0.5 mg every 72 hours
- CrCl <10 mL/min or hemodialysis/CAPD: 0.5 mg every 7 days
For Lamivudine-Refractory or Decompensated Liver Disease (Standard 1 mg dose):
- CrCl ≥50 mL/min: 1 mg once daily
- CrCl 30 to <50 mL/min: 0.5 mg once daily OR 1 mg every 48 hours
- CrCl 10 to <30 mL/min: 1 mg every 72 hours
- CrCl <10 mL/min or hemodialysis/CAPD: 1 mg every 7 days
For hemodialysis patients, administer entecavir after the hemodialysis session. 1
Key Clinical Considerations
Entecavir as Preferred Agent in AKI
Entecavir is specifically preferred over tenofovir disoproxil fumarate (TDF) in treatment-naïve patients with renal dysfunction or at risk for renal impairment. 2 The 2022 KASL guidelines explicitly recommend entecavir, tenofovir alafenamide (TAF), or besifovir over TDF when estimated glomerular filtration rate is <60 mL/min/1.73 m², when dipstick proteinuria or urine albumin/creatinine ratio exceeds 30 mg/g, or when serum phosphate is low (<2.5 mg/dL). 2
Renal Safety Profile
Real-world evidence demonstrates that entecavir does not worsen renal function and may actually improve it in patients with chronic kidney disease. 3 In a multicenter study of 273 HBV-infected patients, those with CKD stages G3-5 showed restoration of estimated glomerular filtration rate over time during entecavir treatment, contrasting with patients without renal dysfunction. 3
Entecavir has demonstrated high efficacy and safety even in hemodialysis patients, with 100% of hemodialysis patients in one study achieving viral suppression without virological breakthrough. 3
Monitoring Requirements
The AASLD guidelines mandate dose adjustment based on renal function and creatinine clearance as recommended by manufacturers. 2 For patients on any nucleos(t)ide analogue therapy, renal safety monitoring should include:
- Serum creatinine
- Serum phosphorus
- Urine glucose
- Urine protein
These parameters should be assessed before treatment initiation and periodically thereafter, with more frequent monitoring in patients at high risk for renal dysfunction or with preexisting renal impairment. 2
Important Caveats
Lamivudine-Resistant Patients
Exercise caution when using entecavir in lamivudine-resistant patients, as the risk of entecavir resistance is significantly higher in this population. 4 In a study of patients switched from TDF to entecavir, the 5-year cumulative probability of entecavir resistance was 0% in lamivudine-naïve patients but 11% in lamivudine-resistant patients (P=0.018). 4
For lamivudine-resistant patients with AKI, consider tenofovir alafenamide (TAF) as an alternative if available, as it maintains efficacy against lamivudine-resistant strains without the nephrotoxicity concerns of TDF. 2
Administration Timing
Entecavir must be administered on an empty stomach—at least 2 hours after a meal and 2 hours before the next meal—to ensure optimal absorption. 1 This is a critical detail often overlooked in clinical practice but essential for therapeutic efficacy.
Virological Efficacy in Renal Impairment
Despite dose reductions necessitated by renal impairment, entecavir maintains excellent virological efficacy. 3 Studies show that HBV DNA disappearance rates and ALT normalization are similar between patients with and without renal dysfunction, with overall serum HBV-DNA disappearance rates of 84.2%, 94.0%, and 96.2% at 1,2, and 3 years respectively. 3